x
ServiziMenu principaleHome
You are here: Home > Events > Past events > 2015 > Molecular Diagnostics, Genomics and Epigenetics in Clinical Oncology
Print

Description

Chairs: M.S. Aapro, CH - J. Gligorov, FR

The understanding of cancer biology and development of specific immunological and “targeted” treatments is revolutionizing cancer treatment. To optimize the use of these therapeutic advances there is a clear need to define the disease of the patient more precisely.

The event will try to find answers to questions such as which parameters are of importance for the evaluation of patient prognosis and prediction of efficacy of the treatment. The Faculty will explain what can be asked from new methods, what do they bring today and what will they bring tomorrow.



LEARNING OBJECTIVES
• Update the knowledge of the implications for practice and clinical research  (tools to be used, tools still in research, areas where no tools are yet available)
• Understanding epigenetics and genomics research and their impact on cancer prognosis and therapy response (prediction)


MAIN TOPICS
• Epigenetics
• Pharmacogenomics
• Lung cancer
• Colorectal cancer
• Prostate cancer
• Breast cancer



  You might be interested in considering also the following conference:  

  8TH EUROPEAN MEETING ON MOLECULAR DIAGNOSTICS
  14-16 October 2015, Noordwijk aan Zee, The Netherlands
  Website: www.molecularmeeting.com
 



General information

ORGANISING SECRETARIAT
Programme, organisation and sponsorship

Luis Carvalho
European School of Oncology (ESO)
Piazza Indipendenza 2
6500 Bellinzona
ph +41 91 820 09 58
e-mail: lcarvalho@eso.net

 

Programme and registrations
Laura Richetti
e-mail: lrichetti@eso.net
Tel: +41 91 820 09 51

 

VENUE
Radisson Blu ES. Hotel
Via Turati, 171 - Rome, Italy
Phone: +39 06 444 841
Website: www.radissonblu.com/eshotel-rome


OFFICIAL LANGUAGE
The official language will be English. No translation will be provided.


INSURANCE
The organisers bear no responsibility for untoward events in relation to the participation in the Conference. Participants are advised to take out their own personal and travel insurance.


WI-FI ACCESS
Free Wi-Fi internet access in all areas of the conference venue is available.



REGISTRATION DESK, OPENING HOURS
Friday, 27 November 8:30-19:00
Saturday, 28 November 8:00-13:30


EXHIBITION, OPENING HOURS

Friday, 27 November 8:30-19:00
Saturday, 28 November 8:00-13:30



ACKNOWLEDGEMENT

ESO wishes to extend its appreciation to the sponsor for having granted its participation and support to the conference:

           

          

SPONSORED SATELLITE SYMPOSIUM

 
Friday, 27 November 2015 - 17:45-18:45   
Sponsored satellite symposium
Genomic Health
The role of big data and population based studies in personalised medicine
Chairs: M. Aapro, CH - J.  Gligorov, FR

17:45 Opportunities and challenges in utilizing big data to generate evidence   
M. Lawler, UK
          
 18:00 5-year outcomes data evaluating genomic testing in population based cohort    
S. Stemmer, IL

 18:15 Utilizing population based cohorts to assess biomarkers and quality initiatives   
C. van de Velde, NL

 18:30 Panel Discussion   
All speakers

 18:45 Conclusion 

Symposium faculty:
M. Lawler, Queens University Hospital, Queens, UK
S. Stemmer, Tel Aviv University, Tel Aviv, IL
C. van de Velde, Leiden University Medical Center, Leiden, NL


 

Faculty list

 

FACULTY
M.S. Aapro, IMO Clinique de Genolier, CH
G. Curigliano,
European Institute of Oncology, Milan, Italy
R. Danesi,
University of Pisa, Pisa, IT
J. De Bono,
The Royal Marsden Hospital, Sutton, UK
V. Dieras,
Institut Curie, Paris, FR
E. Felip,
Vall d'Hebron University Hospital, Barcelona, ES
J. Gligorov,
Hopitaux Universitaires Paris Est Tenon, Paris, FR
L. Lacroix,
Institut Gustave Roussy, Villejuif, FR
P. Laurent-Puig, Université Paris-Descartes INSERM, Paris, FR
N. Mottet,
Hôpital Nord, Saint Etienne, France
F. Penault-Llorca,
Centre Jean Perrin, Clermont-Ferrand, FR
J. Remon,
Institut Gustave Roussy, Le Plessis Robinson, FR
D. Rossi,
Amedeo Avogadro University of Eastern Piedmont, Novara, IT
H. Rugo,
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US
E. Van Cutsem, University Hospital Leuven, Leuven, BE
Y. Yarden, The Weizmann Institute of Science, Rehovot, IL

Programme


27 November

   
9:45 Welcome and introduction
M.S. Aapro, CH - J. Gligorov, FR
INTRODUCTORY SESSION
10:00 Understanding next generation sequencing
 10:20 Discussion
  

L. Lacroix, FR

10:30 Coffee break
WHERE DO WE STAND ON LUNG CANCER?

 10:50 Lung cancer as a model for the development of personalized medicine: What should you ask from your pathologist in order to apply specific treatments
 11:10
 Discussion based on a clinical case
  E. Felip, ES
 11:30 Future developments in medical lung cancer therapy
 11:50  Discussion based on a clinical case
  J. Remon, FR
WHERE DO WE STAND ON PROSTATE CANCER?
 12:10 How to decide the medical treatment of prostate cancer?
 12:30 Discussion based on a clinical case
 
 N. Mottet, FR
 12:50 Genomics: An essential aspect for haemato-oncologists
 13:10 Discussion
  J. de Bono, UK
 13:20 Lunch
WHERE DO WE STAND ON COLORECTAL CANCER?

 14:20 
About k-ras, b-raf and beyond as predictive markers in colon and rectal cancer
 14:40 Discussion based on a clinical case
  P. Lauren-Puig, FR
 15:00 How does the clinician use these data to best treat colon and rectal cancer?
 15:20 Discussion based on a clinical case
  E. Van Cutsem, BE
 15:40 
Genomics: An essential aspect for haemato-oncologists
 16:00 D. Rossi, IT
 16:20 Coffee break
 16:40 Epigenetics and circulating tumour DNA: A frontier in cancer biology
 17:10 Discussion
  R. Danesi, IT
 17:30 Days's closure
M. Aapro, CH - J. Gligorov, FR

 17:45-
18:45

 Sponsored satellite symposium
(Details are available under the menu Information)
   

 

28 November

   
8:30
 Introduction
M. Aapro, CH - J. Gligorov, FR  
 8:40 Understanding drivers of cancer cell development
 9:10 Discussion
  Y. Yarden, IL
WHERE DO WE STAND IN BREAST CANCER?
9:20 Classic pathology of breast cancer: Triple negatives with good prognosis and rare subtypes
9:40
  Discussion
  F. Penault-Llorca, FR
9:50   Molecular characterization of breast cancer: When is  it needed?
10:10  Discussion
  F. Penault-Llorca, FR
10:20 Coffee break
10:40 Neoadjuvant/adjuvant therapy: How to manage early triple-negative tumours
11:10
  Discussion based on a clinical case
  H. Rugo, US
 11:30 Treatment of HER-2 positive disease in the (neo-) adjuvant settings: What alternatives?
 11:50  Discussion based on a clinical case
  V. Dieras, FR
 12:10 Chemotherapy for luminal A tumours?
 12:30  Discussion based on a clinical case
  G. Curigliano, IT
 13:00
 Close
M. Aapro, CH - J. Gligorov, FR
 13:10 Lunch and departures
   
   
   
   
   

 

Follow us